Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.46 |
| ▸ | ADH1B | P00325 | 2/20 | 0.46 |
| ▸ | ADH1C | P00326 | 2/20 | 0.46 |
| ▸ | ADH1A | P07327 | 2/20 | 0.46 |
| ▸ | ADH7 | P40394 | 2/20 | 0.46 |
| ▸ | ADH4 | P08319 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL312840 | 0.98 | KDM1A (0.54) | KDM1ATSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL8938918 | 0.81 | — | — | |
| SCHEMBL8938917 | 0.81 | — | — | |
| SCHEMBL24157573 | 0.80 | KDM1A (0.64) | KDM1ATSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL22157514 | 0.80 | KDM1A (0.58) | KDM1ATSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL20037699 | 0.80 | KDM1A (0.58) | KDM1ATSHRALDH1A1EPHX1ADH1B | |
| Hydrochloric Acid SCHEMBL9052774 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL9052779 | 0.79 | — | — | |
| SCHEMBL9213042 | 0.78 | KDM1A (0.61) | KDM1ATSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL10827259 | 0.78 | KDM1A (0.56) | KDM1ATSHRALDH1A1EPHX1ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1269985-B1 | Wipe and uses thereof in the cosmetics field | OREAL (FR) | 2005-11-30 | — | — | EP | claimed |
| EP-1269985-A1 | Wipe and uses thereof in the cosmetics field | L'OREAL (FR) | 2003-01-02 | — | — | EP | claimed |
| EP-0976384-B1 | Cosmetic and/or dermatological biphasic composition for eyes make-up removal | OREAL (FR) | 2001-07-25 | — | — | EP | claimed |
| EP-0976384-A1 | Cosmetic and/or dermatological biphasic composition for eyes make-up removal | L'OREAL (FR) | 2000-02-02 | — | — | EP | claimed |
| EP-0850634-B1 | Preservative system and its use in a cosmetic or pharmaceutical composition | OREAL (FR) | 1999-05-26 | — | — | EP | claimed |
| EP-0850634-A1 | Preservative system and its use in a cosmetic or pharmaceutical composition | L'OREAL (FR) | 1998-07-01 | — | — | EP | claimed |
| US-20190110977-A1 | PROCESS FOR TREATMENT OF KERATINOUS MATERIALS AND KIT FOR FORMULATION OF A COSMETIC PRODUCT | L'OREAL (FR) | 2019-04-18 | — | — | US | disclosed |
| EP-2335683-B1 | Cosmetic kit formulation | L'ORÉAL (FR) | 2018-02-28 | — | — | EP | disclosed |
| CN-106132531-A | Improvements in or relating to organic compounds | 奇华顿股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-1606618-B | Novel alkali protease formed by bacillus gibsonii (DSM 14393) and washing and cleaning agents containing said novel alkali protease | HENKEL KGAA | 2013-03-13 | — | — | CN | disclosed |
| EP-2335683-A1 | Cosmetic kit formulation | L'Oréal (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20110142897-A1 | PROCESS FOR TREATMENT OF KERATINOUS MATERIALS AND KIT FOR FORMULATION OF A COSMETIC PRODUCT | L'OREAL (FR) | 2011-06-16 | — | — | US | disclosed |
| CN-1608129-B | Alkaline protease from bacillus sp. (DSM 14392) and uses thereof | HENKEL KGAA | 2010-06-16 | — | — | CN | disclosed |
| EP-0976384-B1 | Cosmetic and/or dermatological biphasic composition for eyes make-up removal | OREAL (FR) | 2001-07-25 | — | — | EP | disclosed |
| EP-0976384-A1 | Cosmetic and/or dermatological biphasic composition for eyes make-up removal | L'OREAL (FR) | 2000-02-02 | — | — | EP | disclosed |
| EP-0976384-A1 | Cosmetic and/or dermatological biphasic composition for eyes make-up removal | L'OREAL (FR) | 2000-02-02 | — | — | EP | disclosed |
| EP-0850634-B1 | Preservative system and its use in a cosmetic or pharmaceutical composition | OREAL (FR) | 1999-05-26 | — | — | EP | disclosed |
| US-5900227-A | CAN BE REACTED WITH A FREE RADICAL IN SOLUTION TO FORM A SPIN ADDUCT WHICH IS STABLE AND READILY DETECTABLE BY ELECTRON PARAMAGNETIC RESONANCE (EPR) SPECTROSCOPY. | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1999-05-04 | — | — | US | disclosed |
| EP-0850634-A1 | Preservative system and its use in a cosmetic or pharmaceutical composition | L'OREAL (FR) | 1998-07-01 | — | — | EP | disclosed |
| EP-0850634-A1 | Preservative system and its use in a cosmetic or pharmaceutical composition | L'OREAL (FR) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190110977-A1 | PROCESS FOR TREATMENT OF KERATINOUS MATERIALS AND KIT FOR FORMULATION OF A COSMETIC PRODUCT | CUTA, KRT18, KIT | KDM1A 443/4885TSHR 3836/4885ALDH1A1 1955/4885 |
| US-20110142897-A1 | PROCESS FOR TREATMENT OF KERATINOUS MATERIALS AND KIT FOR FORMULATION OF A COSMETIC PRODUCT | CUTA, KRT18, KIT | KDM1A 443/4885TSHR 3836/4885ALDH1A1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.